Research programme: neurological and neuromuscular disease therapeutics - Biogen Idec/Ionis Pharmaceuticals

Drug Profile

Research programme: neurological and neuromuscular disease therapeutics - Biogen Idec/Ionis Pharmaceuticals

Alternative Names: IONIS BIIB5Rx; IONIS BIIB6Rx; ISIS BIIB3Rx

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Biological factors; Small molecules
  • Mechanism of Action Gene expression modulators; Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurodegenerative disorders
  • Research Neurological disorders; Neuromuscular disorders

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 06 Nov 2014 Preclinical trials in Neurodegenerative disorders in USA (unspecified route) prior to November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top